The DUS1L Knockout A2780 Polyclonal Cells product comprises a heterogeneous population of CRISPR/Cas9-edited human ovarian carcinoma cells carrying targeted disruption of the DUS1L gene. As a polyclonal knockout pool, this product provides a genetically diverse loss-of-function model suitable for studying the role of tRNA dihydrouridine modification in cancer biology. The CRISPR/Cas9 system was employed to introduce gene-disrupting edits across the DUS1L locus, generating a pooled knockout population without single-cell cloning. This polyclonal format preserves cellular heterogeneity while enabling robust functional analyses of DUS1L-dependent processes.
Derived from an untreated patient with ovarian endometrioid adenocarcinoma, the A2780 cell line exhibits an epithelial morphology and serves as a widely utilized model for ovarian cancer research. These tumor-derived epithelial cells retain key characteristics of the original malignancy, making them a relevant host for investigating oncogenic mechanisms and therapeutic responses. The A2780 background has been extensively employed in drug sensitivity studies, proliferation assays, and mechanistic investigations of ovarian cancer, providing a well-characterized context for genetic perturbation.
DUS1L encodes a tRNA dihydrouridine synthase that catalyzes the reduction of uridine to dihydrouridine in the D-loop of specific tRNA substrates, including tRNA-Leu and tRNA-Ser. This post-transcriptional modification enhances tRNA structural flexibility and promotes efficient translation elongation by facilitating ribosome interactions. The enzyme functionally interfaces with translation machinery components and ribosome-associated factors, operating within the tRNA modification pathway to sustain accurate protein synthesis. Disruption of DUS1L is predicted to impair dihydrouridine modification, potentially altering the function of target tRNAs and downstream translation regulation.
In the A2780 ovarian carcinoma background, DUS1L knockout is expected to perturb tRNA modification-dependent translation, thereby impacting protein homeostasis and cell proliferation. Given the heightened translational demand of rapidly dividing tumor cells, loss of DUS1L may selectively compromise cellular fitness and stress responses, offering a relevant model to probe the intersection between tRNA biology and oncogenesis. This system allows researchers to investigate how aberrant tRNA modification contributes to ovarian cancer pathophysiology and to explore synthetic lethal interactions with existing therapies.
This polyclonal knockout model is well-suited for functional studies of tRNA dihydrouridine modification in ovarian cancer, including translational control research, drug screening for tRNA modification inhibitors, and biomarker discovery. Representative assays include Western blotting for downstream target validation, RT-qPCR for transcript-level analyses, LC?MS for quantifying tRNA dihydrouridine levels, proliferation assays, translation efficiency measurements, and drug sensitivity testing. These applications enable detailed mechanistic elucidation and high?content phenotypic screening. For further details, please contact Ascent Research.
